SG Americas Securities LLC Sells 145,901 Shares of OPKO Health, Inc. $OPK

SG Americas Securities LLC lowered its stake in shares of OPKO Health, Inc. (NASDAQ:OPK) by 41.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 206,375 shares of the biotechnology company’s stock after selling 145,901 shares during the period. SG Americas Securities LLC’s holdings in OPKO Health were worth $272,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. GM Advisory Group LLC bought a new position in shares of OPKO Health in the 1st quarter worth $33,000. Kapitalo Investimentos Ltda purchased a new position in OPKO Health in the second quarter valued at about $41,000. Voleon Capital Management LP bought a new position in OPKO Health in the first quarter worth about $45,000. Brighton Jones LLC lifted its position in shares of OPKO Health by 29.1% during the second quarter. Brighton Jones LLC now owns 38,916 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 8,775 shares during the last quarter. Finally, Strs Ohio bought a new stake in shares of OPKO Health in the 1st quarter valued at about $53,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Phillip Md Et Al Frost bought 580,000 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The stock was purchased at an average price of $1.33 per share, with a total value of $771,400.00. Following the completion of the acquisition, the chief executive officer directly owned 216,706,448 shares of the company’s stock, valued at $288,219,575.84. This trade represents a 0.27% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders bought 1,843,300 shares of company stock valued at $2,421,491 in the last three months. Company insiders own 49.69% of the company’s stock.

OPKO Health Price Performance

Shares of OPK opened at $1.34 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The company’s fifty day moving average price is $1.43 and its 200-day moving average price is $1.38. OPKO Health, Inc. has a 1-year low of $1.11 and a 1-year high of $2.04. The firm has a market capitalization of $1.02 billion, a PE ratio of -5.34 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.05. OPKO Health had a negative return on equity of 13.62% and a negative net margin of 28.10%.The company had revenue of $151.67 million during the quarter, compared to analyst estimates of $165.74 million. During the same quarter last year, the business posted $0.03 EPS. The firm’s quarterly revenue was down 12.6% on a year-over-year basis. On average, equities research analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of OPKO Health in a research note on Thursday, November 20th. They set a “neutral” rating for the company. Wall Street Zen raised shares of OPKO Health from a “strong sell” rating to a “hold” rating in a report on Saturday, November 1st. Zacks Research upgraded OPKO Health from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $1.60 target price (down from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $2.28.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.